Evidence for Dopamine Deamination by Both Type A and Type B Monoamine Oxidase in Rat Brain in Vivo and for the Degree of Inhibition of Enzyme Necessary for Increased Functional Activity of Dopamine and 5-hydroxytryptamine

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 1977 Jul 1

PMID 890205

Citations 36

Authors

A R Green

B D Mitchell

A F Tordoff

M B Youdim

Affiliations

Soon will be listed here.

Citing Articles

Development of PPARγ Agonists for the Treatment of Neuroinflammatory and Neurodegenerative Diseases: Leriglitazone as a Promising Candidate.

Pizcueta P, Vergara C, Emanuele M, Vilalta A, Rodriguez-Pascau L, Martinell M Int J Mol Sci. 2023; 24(4).

PMID: 36834611 PMC: 9961553. DOI: 10.3390/ijms24043201.

Revisiting the Role of Astrocytic MAOB in Parkinson's Disease.

Nam M, Sa M, Ju Y, Park M, Lee C Int J Mol Sci. 2022; 23(8).

PMID: 35457272 PMC: 9028367. DOI: 10.3390/ijms23084453.

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease.

Jost W J Neural Transm (Vienna). 2022; 129(5-6):723-736.

PMID: 35107654 PMC: 9188534. DOI: 10.1007/s00702-022-02465-w.

On the practical aspects of characterising monoamine oxidase inhibition in vitro.

Holt A J Neural Transm (Vienna). 2018; 125(11):1685-1705.

PMID: 30374594 DOI: 10.1007/s00702-018-1943-8.

Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.

Youdim M J Neural Transm (Vienna). 2018; 125(11):1719-1733.

PMID: 30341696 DOI: 10.1007/s00702-018-1942-9.

References

Houslay M, Tipton K . Multiple forms of monoamine oxidase: fact and artefact. Life Sci. 1976; 19(4):467-77. DOI: 10.1016/0024-3205(76)90224-1. View

Youdim M, Collins G, Sandler M, Bevan Jones A, PARE C, Nicholson W . Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature. 1972; 236(5344):225-8. DOI: 10.1038/236225b0. View

Green A, Grahame-Smith D . The role of brain dopamine in the hyperactivity syndrome produced by increased 5-hydroxytryptamine synthesis in rats. Neuropharmacology. 1974; 13(10-11):949-59. DOI: 10.1016/0028-3908(74)90086-0. View

Yang H, Neff N . The monoamine oxidases of brain: selective inhibition with drugs and the consequences for the metabolism of the biogenic amines. J Pharmacol Exp Ther. 1974; 189(3):733-40. View

Green A, Kelly P . Evidence concerning the involvement of 5-hydroxytryptamine in the locomotor activity produced by amphetamine or tranylcypromine plus L-DOPA. Br J Pharmacol. 1976; 57(1):141-7. PMC: 1667008. DOI: 10.1111/j.1476-5381.1976.tb07664.x. View

Grahame-Smith D . Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem. 1971; 18(6):1053-66. DOI: 10.1111/j.1471-4159.1971.tb12034.x. View

Green A, Youdim M . Effects of monoamine oxidase inhibition by clorgyline, deprenil or tranylcypromine on 5-hydroxytryptamine concentrations in rat brain and hyperactivity following subsequent tryptophan administration. Br J Pharmacol. 1975; 55(3):415-22. PMC: 1666694. DOI: 10.1111/j.1476-5381.1975.tb06946.x. View

Curzon G, Green A . Rapid method for the determination of 5-hydroxytryptamine and 5-hydroxyindoleacetic acid in small regions of rat brain. Br J Pharmacol. 1970; 39(3):653-5. PMC: 1702616. DOI: 10.1111/j.1476-5381.1970.tb10373.x. View

Chang C . A SENSITIVE METHOD FOR SPECTROPHOTOFLUOROMETRIC ASSAY OF CATECHOLAMINES. Int J Neuropharmacol. 1964; 3:643-9. DOI: 10.1016/0028-3908(64)90089-9. View

10.

LOWRY O, ROSEBROUGH N, FARR A, RANDALL R . Protein measurement with the Folin phenol reagent. J Biol Chem. 1951; 193(1):265-75. View

11.

EVERETT G, Borcherding J . L-DOPA: effect on concentrations of dopamine, norepinephrine, and serotonin in brains of mice. Science. 1970; 168(3933):847-50. View

12.

Ekstedt B . Substrate specificity of the different forms of monoamine oxidase in rat liver mitochondria. Biochem Pharmacol. 1976; 25(10):1133-8. DOI: 10.1016/0006-2952(76)90359-2. View